#ECTRIMS2021 — Rituximab as First RRMS Therapy Outperforms Others

#ECTRIMS2021 — Rituximab as First RRMS Therapy Outperforms Others

309108

#ECTRIMS2021 — Rituximab as First RRMS Therapy Outperforms Others

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13–15. Go here to see the latest stories from the conference. People with relapsing-remitting multiple sclerosis (RRMS) who are first treated with rituximab are less likely to have disease relapses and brain lesions as compared with patients on other therapies, according to new data from the COMBAT-MS…

You must be logged in to read/download the full post.